Last reviewed 2026-04-23 · How we verify

biological therapy

This biological therapy works by targeting the immune system to treat cancer.

This biological therapy works by targeting the immune system to treat cancer. Used for Metastatic breast cancer.

At a glance

Mechanism of action

It does this by stimulating the immune system to recognize and attack cancer cells, with the goal of reducing tumor growth and improving patient outcomes.

Approved indications

• Metastatic breast cancer

Common side effects

• Fatigue
• Nausea
• Diarrhea

Key clinical trials

• Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
• Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (PHASE2)
• Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors (PHASE1)
• Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (PHASE2)
• Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE1)
• Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.